ML281
Based on 2 publication(s) in Google Scholar
ML281 is a highly selective inhibitor of serine/threonine kinase 33 (STK33) with an IC50 value of 14 nM. ML281 shows 700-fold selectivity over PKA and 550-fold over AurB. ML281 exerts core mechanism by inhibiting STK33: in small cell lung cancer, ML281 downregulates RPS6/BAD signaling phosphorylation, induces apoptosis, and suppresses proliferation, invasion. ML281 reduces STK33-mediated 4-hydroxyphenylpyruvate dioxygenase (HPD) phosphorylation in tyrosinemia . ML281 is suitable for research on STK33 function, KRAS mutation-related cancers (pancreatic cancer, colon cancer, lung adenocarcinoma, etc.), small cell lung cancer, and tyrosinemia-related damage
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.04%
- CAS No.: 1404437-62-2
- Formule: C22H19N3O2S
- Masse moléculaire:389.47
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) ML281
More-
WB
Voir tous les produits spécifiques à Isoform Aurora Kinase
More
Activité biologique
Description
IC50 & Target
[1]|
PKA |
Aurora B |
bad |
In Vitro
ML281 (10 μM; 72 hours) suppresses cell viability of NCI-H446 cells[3].
ML281 exhibits potent inhibitory activity against purified recombinant serine/threonine kinase 33 (STK33) (IC50 = 14 nM) [1].
ML281 (0.01-10 μM) has no significant effect on the viability of KRAS-dependent (NOMO-1, SKM-1) and KRAS-independent (THP-1, U937) acute myeloid leukemia-derived cell lines, ML281 does not exhibit selective cytotoxicity against KRAS-dependent cancer cells.[1].
ML281 (10 μM; 72 h) suppresses RPS6/BAD signaling pathway in human small cell lung cancer NCI-H446 cells[1].
ML281 (2.5-12.5 μM; 48 h) decreases T382 site phosphorylation of 4-hydroxyphenylpyruvate dioxygenase (HPD) and increases HPD protein expression in a dosage-dependent manner in human fetal hepatocyte LO2 cells[4].
ML281 (10 μM; 48 h) abrogates enhanced HPD T382 phosphorylation and HPD degradation in Ttc36-deficient mouse primary hepatocytes[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:NCI-H446 cells
-
Concentration:10 μM
-
Incubation Time:72 hours
-
Result:Suppressed cell viability of NCI-H446 cells.
-
Cell Line:LO2 cells
-
Concentration:2.5 μM, 5 μM, 7.5 μM, 10 μM, 12.5 μM
-
Incubation Time:48 h
-
Result:Decreased HPD T382 phosphorylation, increased HPD protein expression in a dosage-dependent manner; no effect on HPD T382A mutant phosphorylation.
-
Cell Line:Ttc36-/- mouse primary hepatocytes
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Abrogated enhanced HPD T382 phosphorylation and HPD degradation induced by TTC36 deficiency.
-
Cell Line:NCI-H446 cells
-
Concentration:10 μM
-
Incubation Time:72 hours
-
Result:Decreased phosphorylation of RPS6 and BAD, increased expression of cleaved caspase 9.
Chemical Information
-
CAS No. 1404437-62-2
-
Appearance Solid
-
Masse moléculaire 389.47
-
Formule C22H19N3O2S
-
Color White to off-white
-
SMILES
O=C1NC2=CC=CC=C2N=C1C3=CC(C(C)C)=CC=C3NC(C4=CC=CS4)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
HPD degradation regulated by the TTC36-STK33-PELI1 signaling axis induces tyrosinemia and neurological damage. [Abstract]2019 Sep 19;10(1):4266. PMID: 31537781 -
Neoplasma
Knockdown of human serine/threonine kinase 33 suppresses human small cell lung carcinoma by blocking RPS6/BAD signaling transduction. [Abstract]2017;64(6):869-879. PMID: 28895411
ML281 purchased from MedChemExpress. Usage Cited in: Neoplasma. 2017;64(6):869-879. [Abstract]
Representative images and analysis results of western blotting validation after incubation with ML281.
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (256.76 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
-
Fiche technique (285 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5676 mL | 12.8380 mL | 25.6759 mL | 64.1898 mL |
| 5 mM | 0.5135 mL | 2.5676 mL | 5.1352 mL | 12.8380 mL | |
| 10 mM | 0.2568 mL | 1.2838 mL | 2.5676 mL | 6.4190 mL | |
| 15 mM | 0.1712 mL | 0.8559 mL | 1.7117 mL | 4.2793 mL | |
| 20 mM | 0.1284 mL | 0.6419 mL | 1.2838 mL | 3.2095 mL | |
| 25 mM | 0.1027 mL | 0.5135 mL | 1.0270 mL | 2.5676 mL | |
| 30 mM | 0.0856 mL | 0.4279 mL | 0.8559 mL | 2.1397 mL | |
| 40 mM | 0.0642 mL | 0.3209 mL | 0.6419 mL | 1.6047 mL | |
| 50 mM | 0.0514 mL | 0.2568 mL | 0.5135 mL | 1.2838 mL | |
| 60 mM | 0.0428 mL | 0.2140 mL | 0.4279 mL | 1.0698 mL | |
| 80 mM | 0.0321 mL | 0.1605 mL | 0.3209 mL | 0.8024 mL | |
| 100 mM | 0.0257 mL | 0.1284 mL | 0.2568 mL | 0.6419 mL |
Keywords
- ML281
- 1404437-62-2
- ML 281
- ML-281
- STK33
- PKA
- Aurora Kinase
- Bcl-2 Family
- Apoptosis
- STK33 inhibitor
- NCI-H446 cells
- DMS153 cells
- LO2 cells
- NOMO-1 cells
- SKM-1 cells
- THP-1 cells
- U937 cells
- BALB/c-nu mice
- small cell lung cancer (SCLC)
- tyrosinemia type III
- KRAS-mutant cancers
- pancreatic cancer
- colon cancer
- lung adenocarcinoma
- neurological damage
- downregulated RPS6/BAD signaling pathway
- stabilize 4-hydroxyphenylpyruvate dioxygenase (HPD) expression
- apoptosis
- suppressed tumor cell proliferation
- inhibited tumor cell invasion
- suppressed xenograft tumor growth
- Inhibitor
- inhibitor
- inhibit